PDGFRB and renal cell carcinoma: A large number of multikinase TKIs with inhibitory activity toward PDGFR are used to target stromal PDGFR expression, including sorafenib for hepatocellular carcinoma (HCC), renal cell carcinoma (RCC), and radioiodine‐refractory DTC and pazopanib for RCC and soft tissue sarcoma (STS).